Real-World Outcomes of Ocrelizumab and Ofatumumab Treatment in Pediatric-Onset Multiple Sclerosis. (PubMed, Paediatr Drugs) - Sep 23, 2026 - "These results provide descriptive real-word data on the use of ocrelizumab and ofatumumab, especially when used as a first-line DMT in pediatric-onset multiple sclerosis. Although limited by a short follow-up period, our real-world findings provide safety and effectiveness data to inform DMT selection and shared decision making with families."
Journal • Real-world evidence • CNS Disorders • Infectious Disease • Multiple Sclerosis • Pediatrics
|
|
Alexandra B Kornbluh; Claire Har; Hayley Roper; Ilana Kahn; Vivien X Xie Cherng
|